Skip to main content

Vinorelbine

  • Chapter
  • 91 Accesses

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. Dorr RT, Bool KL: Antidote studies of vinorelbine-induced skin ulceration in the mouse. Cancer Chemother Pharmacol 36: 290–292, 1995.

    Article  PubMed  CAS  Google Scholar 

  2. Bertelli G, Dini D, Forno GB, et al: Hyaluronidase as an antidote to extravasation of vinca alkaloids: clinical results. J Cancer Res Clin Oncol 120: 505–506, 1994.

    Article  PubMed  CAS  Google Scholar 

  3. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a european multicenter trial including 612 patients. J Clin Oncol 12: 360–367, 1994.

    PubMed  Google Scholar 

Secondary literature

  1. Gain M, Melzer S, Meyer-Jürshof A, et al: Vinorelbin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 4: 39, 2000.

    Google Scholar 

  2. Berdel WE, Schmoll HJ, Büchele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.

    Google Scholar 

  3. Summary of product characteristics Navelbine® (Austria), Boehringer Ingelheim Austria, August 1999.

    Google Scholar 

  4. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  5. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  6. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.

    Google Scholar 

  7. Dorr RT, Von Hoff DD: Drug monographs: vinorelbine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 966–969, 1994.

    Google Scholar 

  8. Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Vinorelbine. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_54

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3710-9_54

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3712-3

  • Online ISBN: 978-3-7091-3710-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics